Results 101 to 110 of about 1,470 (198)

Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis

Frontiers in Immunology
Anti-GQ1b antibody syndrome is a spectrum of autoimmune neurological disorders that includes Miller Fisher syndrome, Guillain-Barré syndrome (GBS) with ophthalmoplegia, Bickerstaff brainstem encephalitis, and acute ophthalmoplegia without ataxia.
Keiko Watanabe, Seiya Takahashi, Akane Kanda, Takuya Watanabe, Yuki Kakinuma, Satoshi Yano, Ryuta Kinno, Ryuta Kinno   +7 more
doaj   +1 more source

Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report

Therapeutic Advances in Neurological Disorders
Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness. Severe patients may develop life-threatening respiratory failure and experience crisis.
Zhouao Zhang, Mingjin Yang, Tiancheng Luo, Xue Du, Zhouyi Wang, Xiaoyu Huang, Yong Zhang   +6 more
doaj   +1 more source

Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis

Frontiers in Neurology
BackgroundAs targeted drug development in myasthenia gravis (MG) continues to advance, it is important to compare the efficacy of these drugs for better clinical decision-making. However, due to the varied regimens and dosages used in clinical trials for
Huahua Zhong, Zhijun Li, Xicheng Li, Zongtai Wu, Chong Yan, Sushan Luo, Chongbo Zhao   +6 more
doaj   +1 more source

Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report

BMC Neurology
Background Guillain-Barré syndrome (GBS) is a peripheral neuropathy mediated by immunoglobulin G (IgG) autoantibodies, which can cause acute flaccid paralysis. Miller-Fisher syndrome (MFS) is a variant of GBS, and in some cases, MFS may overlap with GBS (
Bai Qi Hu, Sen Xiang Wu, Qiao Wen Tong, Hua Ye, Ping Ping Jin   +4 more
doaj   +1 more source

The utilization of efgartigimod in the treatment of acute cerebellar ataxia: a case report

Frontiers in Immunology
BackgroundAcute cerebellar ataxia (ACA) is the most common cause of acute ataxia in children and adolescents. It is a cerebellar disorder with multifactorial pathogenesis, often triggered by viral or bacterial infections, as well as autoimmune mechanisms.
Liu L. Yang, Yushuang Ruan, Fucheng Cai, Yuanpeng Xia   +3 more
doaj   +1 more source

Case Report: KLHL11 encephalitis in a female patient with dual primary malignancies of breast and lung cancer: response to FcRn inhibitor therapy [PDF]

Kelch-like protein 11 (KLHL11) encephalitis is a rare clinical condition characterized by autoimmune-mediated encephalitis associated with the presence of KLHL11 antibodies, which commonly presents with ataxia, diplopia, vertigo, hearing loss, and ...
Haoran Xing, Lu Zhao, Lu Zhao, Pan Cui, Pan Cui, Yapeng Li, Yapeng Li, Zhentang Cao, Zhentang Cao   +8 more
core   +1 more source

Rapid neurological recovery in Guillain-Barré syndrome treated with efgartigimod

Scientific Reports
Efgartigimod, a neonatal Fc receptor inhibitor that accelerates IgG degradation, remains understudied in treatment of Guillain-Barré Syndrome (GBS). This study aimed to evaluate the efficacy and safety of efgartigimod in GBS patients.
Yifan Cheng, Wenyu Li, Siyu Xie, Shunyuan Guo, Chunrong Li, Manman Zhang, Yiqi Wang   +6 more
doaj   +1 more source

Case Report: Efgartigimod as an additional therapy for MOG antibody-associated disease overlapping GFAP-IgG [PDF]

IntroductionMyelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) and autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy have received increasing attention in recent years.
Hongru Li, Juanjuan Zhang, Kai Wang, Ling Wei, Yanghua Tian, Yanghua Tian, Yun Zhu   +6 more
core   +1 more source

Dermatologic Manifestations Induced By Immune Responses After Covid-19 Vaccination [PDF]

Immunologic reactions induced by COVID-19 vaccines can manifest in the skin, triggering adverse effects of varying intensity. Although most of these reactions are self-limited and not significant, their identification is complex due to the variability of
León Pallasco , Dayana Aracely, Miranda Solis , Edwin Marcelo, Palma Coque , Elio Joel, Paredes Tobar , Sebastián Oswaldo   +3 more
core   +2 more sources

Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan

Neurology Clinical Practice
Efgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available in Japan not only for the treatment of anti-acetylcholine receptor-positive (AChR+) but also anti-muscle-specific receptor tyrosine kinase (MuSK+) and seronegative generalized MG.
Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Kei Ishizuchi, Daiki Tokuyasu, Hideo Handa, Manato Yasuda, Naoki Kawaguchi, Takashi Kimura, Yasushi Suzuki, Takamichi Sugimoto, Naoya Minami, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +18 more
openaire   +2 more sources